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A major goal of genetic studies of attention deficit
hyperactivity disorder (ADHD) is to identify
individual characteristics that might help segre-
gate the disorder’s inherent heterogeneity. [Mill
et al. (2006); Arch Ger Psychiatry 63:462–469]
recently reported a potentially important associa-
tion between two dopamine-related risk poly-
morphisms (DRD4 variable number tandem
repeat (VNTR) in exon 3 and DAT1 VNTR in the
30 UTR) and lowered IQ in ADHD. The objective of
the current study was to replicate the [Mill et al.
(2006); Arch Ger Psychiatry 63:462–469] findings
in a clinical sample and to extend the analysis to a
large range of alternative SNP markers of puta-
tive ADHD risk alleles identified in a recent study
[Brookes et al. (2006); Mol Genet 11:934–953].
Participants were 1081 children and adolescents
with a research-confirmed combined type ADHD
diagnosis and 1300 unaffected siblings who took
part in the International Multi-centre ADHD
Genetics (IMAGE) project. They were recruited
from multiple settings from across Europe:
Belgium, Britain, Germany, Ireland, Israel,
Netherlands, Spain and Switzerland. The results
were that ADHD was associated with reduced IQ.
However, there was no association between the
two dopamine-related risk polymorphisms and IQ
in either the probands or their siblings. Further-
more, other selected genetic markers previously
demonstrated to be associated with ADHD in this
sample were not associated with IQ. This large
scale study with a clinically ascertained and
regorously diagnosed sample failed to replicate
the association between genetic polymorphisms
in the dopamine system and IQ in ADHD. We also
observed no association of other SNPs with IQ in
ADHD.  2007 Wiley-Liss, Inc.
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INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) is a
complex disorder with growing evidence of heterogeneity in
etiology, pathophysiology and clinical expression [Sonuga-
Barke, 2005]. One of the goals of ADHD genetic research
is to investigate whether genetic factors can explain this
heterogeneity, potentially identifying more homogeneous and
genetically defined subgroups within the clinical phenotype in
a way that could strengthen existing diagnostic approaches
[Castellanos and Tannock, 2002]. One approach to resolving
heterogeneity involves the identification of endophenotypes,
intervening variables that might mediate pathways between
specific genes or clusters of genes and the clinical phenotype
[Stevenson et al., 2005]. In this regard the replicated but
small association between ADHD and functional variants in a
number of genes related to dopamine neurotransmission
[Faraone et al., 2005] has focused attention on the endo-
phenotypic pathways between these genes and the clinical
condition [Bellgrove et al., 2005].
Mill et al. [2006] recently reported data from two epidemio-
logically ascertained cohorts in which children identified as
meeting symptomatic criteria for ADHD and who carried
high risk genotypes for the dopamine transporter (DAT1 or
SLC6A3; two copies of the 10-repeat allele of a VNTR in the 30
UTRof the gene) and thedopamineD4 receptor (DRD4; at least
one copy of the 7-repeat allele of theVNTR in exon3), had lower
IQ relative to other ADHD children in their sample. The
reported effects were striking, with over a 10-point difference
in IQ between the groups in the two independent datasets.
This finding, suggesting as it did a genotypically defined
intellectually impaired subgroup within ADHD, was poten-
tially of considerable significance. However, the non-standard
approach to diagnosis used to characterize children in one of
the samples (children were identified as cases on the basis of
meeting thresholds on either hyperactive/impulsive or inat-
tentive symptoms as reported by the teacher or the parent) and
the very small size of the second sample (in sum 48 children
with ADHD, of whom only 11 had high genotypic risk) makes
replication of these results in larger sampleswith a full clinical
work up and rigorous diagnosis essential.
Since then, Genro et al. [2006] failed to replicate the
association between IQ and the Mill index of genotypic risk
in three samples of clinically diagnosed Brazilian cases;
242 referred children with ADHD, 220 adults with ADHD
and 100 children with ADHD inattentive type, ascertained
from 12 public schools. No significant association was seen in
these samples (P¼ 0.77; P¼ 0.99; P¼ 0.15, respectively). The
current study attempted a further replication of the findings of
Mill et al. [2006] in a very large sample of children and
adolescents with combined typeADHD from families recruited
for the International Multicentre ADHD Genetics project
(IMAGE) [Asherson, 2004]. We extended the analysis of
possible genotypicmarkers of low IQ inADHDby investigating
the possible association with IQ of 55 single nucleotide
polymorphism (SNP) markers, including markers in TPH2,
ARRB2, SYP, ADRB2, HES1, MAOA, NET, and PNMT,
identified as putative genetic risk markers for ADHD in a
recent study of this sample [Brookes et al., 2006].
METHODS
Sample
IMAGE recruited European Caucasian subjects from
twelve specialist clinics in eight countries: Belgium, Germany,
Holland, Ireland, Israel, Spain, Switzerland, and United
Kingdom. Ethical approval for the study was obtained from
National Institute of Health registered ethical review boards
for each center. All ADHD probands and their siblings were
aged 5–17 at the time of entry into the study and access was
required to one or both biological parents for DNA collection.
Entry criteria for probandswere a clinical diagnosis ofDSM-IV
combined subtype ADHD and having one or more full
siblings available for ascertainment of clinical information
and DNA collection. Exclusion criteria applying to both
probands and siblings included autism, epilepsy, IQ< 70,
brain disorders and any genetic or medical disorder associated
with externalizing behaviors that might mimic ADHD. The
overall dataset consisted of 1,246 probands and 1,600 siblings.
Prior to entry into the study, all probands underwent
clinical evaluations by a trained clinician. Diagnostic status
was confirmed using a standardized clinical assessment
(see below). Wherever possible families withdrew stimulant
medication for 1 week prior to research assessments and
ratings were based on medication free periods.
For the purposes of the current analysis probands were
included only if they met research criteria for combined type
diagnosis (948 boys and 133 girls; mean age¼ 10.8 years,
SD¼ 2.76). Unaffected siblings (628 boys and 672 girls; mean
age¼ 11.0 years, SD¼ 3.42) were included in the analysis as
a non-clinical, although correlated, comparison group (i.e., no
diagnosis of ADHD combined, inattentive or hyperactive/
impulsive). The necessary genotypic (DAT1 N¼ 2102: 88% of
total sample; DRD4 N¼ 2295; 88.6%) and IQ data (N¼ 1655)
was available for 702 ADHD cases (628 boys; mean age¼
10.80 years; SD¼ 2.76) and 694 siblings (317 boys; mean
age¼ 10.96; SD¼ 3.43) (Table I).
Attention/Deficit Hyperactivity Disorder Diagnosis
A standardized algorithm was applied to data from the
Parental Account of Childhood Symptoms [Taylor et al., 1991]
to derive each of the 18 DSM-IV ADHD items, providing
operational definitions for each behavioral symptom. The
PACS is a semi-structured, standardized, investigator-based
interview. A trained interviewer rates on a four-point scale the
frequency and severity of symptoms on the basis of parents’
descriptions of the child’s typical behavior in a range of
specified situations (e.g., watching television, reading a book
or comic, playing alone, playing with friends, going to bed,
traveling). Inter-rater reliability is high with product-moment
correlations for pairs of interviewers ranging from 0.79 to 0.96.
The PACS data were combined with items that scored 2 or 3
from the teacher rated Conners’ ADHD subscale [Conners,
2000], to generate the total number of items from the DSM-IV
symptom checklist.
TABLE I. Genotypic Riskin the ADHD and Unaffected Siblings
in Terms of the Presence or Absence of (i) at Least One DRD4 7
Repeat and (ii) 10/10 DAT1
DAT1 10/10
No Yes
At least one DRD4 7 repeat
ADHD combined type
No 190 (27.1%) 282 (40.2%)
Yes 107 (15.2%) 123 (17.5%)
Unaffected siblings
No 188 (27.1%) 244 (35.2%)
Yes 119 (17.1%) 143 (20.6%)
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Intelligence Testing
IQ was measured using Wechsler Intelligence Scales for
Children (WISC-IIIR [Wechsler, 1991]) which were adminis-
tered to each child by centrally trained research workers using
a common protocol. The vocabulary, similarities, picture
completion and block design subtests from the WISC were
used to obtain an estimate of the child’s IQ (prorated
following procedures described by Sattler [1992]). Up to date,
age-appropriate national population norms were available
for each participating site and these were used to derive
standardized estimates of intelligence on the basis of common
algorithms (Table II).
DNA Extraction and Genotyping
DNA was extracted directly from blood samples or cell lines
at Rutgers Cell line and DNA repository in the US. In a few
caseswe used amouth swab sampling technique and extracted
the DNA at the SGDP laboratories in London. For genotyping
of the variable number tandem repeat (VNTR) markers we
used standard PCR protocols according to previous optimized
protocols for the markers used in this study. SNP genotyping
was undertaken by an Illumina custom SNP array in a
previously reported study [Brookes et al., 2006]. In this study
51 candidate genes, incorporating such systems as the
dopamine and serotonin neurotransmitter systems, where
screened for associationwithADHDusing 1,038SNPmarkers.
Of these 1,038, 55 SNPmarkers, in 18 genes, including TPH2,
ARRB2, SYP,ADRB2,HES1,MAOA,NET, andPNMT, had an
association with ADHD with significance values of less than
0.05. The 55 significant SNPs were investigated with
QPDTPHASE [Dudbridge, 2003] for association with IQ in
ADHD probands. QPDT analysis using the UNPHASED
software (www.rfcgr.mrc.ac.uk/fdudbrid/software/unphased)
estimates the covariance within each family assuming a null
hypothesis of no association, with trait and genotypes being
uncorrelated.
RESULTS AND DISCUSSION
As in Mill et al. [2006] ADHD was associated with lower
IQ scores (ADHD mean¼ 100.70, SD¼ 103.41; sibling
mean¼ 103.41, SD¼ 103.41; t(1,653)¼ 3.61; P< 0.0001). This
effect was especially marked for girls (female ADHD mean¼
94.88, SD¼ 16.16; female sibling mean¼ 102.74, SD¼ 13.51;
female t(542)¼ 5.097; P< 0.0001; male ADHD mean¼ 101.51,
SD¼ 15.97; male sibling mean¼ 104.11, SD¼ 15.33; boys
t(1,106)¼ 2.60; P< 0.01). Table I reports data on the presence
of DRD4 (at least one 7 repeat) and DAT1 (10/10 homozygous)
risk genotypes. There was no association between the presence
of DRD4 7 repeat allele and DAT1 10/10. The presence of
genotypic risk in either DRD4 (ADHD probands, F(1, 710)¼
0.14, P> 0.7; unaffected siblings F(1, 696)¼ 1.32; P> 0.2) or
DAT1 (ADHD probands, F(1, 710)¼ 0.33 P> 0.5; unaffected
siblings F(1, 696)¼ 1.20; P> 0.2) alone was not associated with
IQ. Furthermore there was no evidence that these risks acted
together either additively (P> 0.7) or multiplicatively (P> 0.9)
to reduce IQ. The combined genotypic risk index was not
associated with IQ in either the probands or their siblings
(P> 0.5). These effectswereunaffectedby takingaccount of age,
sex or comorbid oppositional defiant disorder (P> 0.3). TheMill
et al. [2006] finding was also not replicated at any of the
individual sites with the current study [data available from
authors on request]. When analysis was extended to children
with inattentive (N¼ 24) and hyperactive/impulsive subtypes
(N¼ 17) and to all children with ADHD combined type within
the total sample (i.e., including affected siblings) not included in
the main analysis but for whom IQ data was available the
findings did not change.
We extended this analysis of genotypic markers of low IQ in
ADHD (probands only) to include all 55 SNPmarkers shown to
have nominal level of association (P< 0.05) within this sample
using IMAGE Illumina SNP array association study [Brookes
et al., 2006]. Essentially no significant correlations between IQ
and genotype were observed in these extended analyses of the
probands when significance levels were corrected for multiple
testing. Only twomarkers displayedP values of less of equal to
0.05: These were both in the SLC9A9 gene (rs6793522 and
rs1900633).However these values fallwell short of significance
when corrected for the number of markers tested (revised
alpha¼P< 0.009). This suggested that there was no true
association between IQ and the genotype of any of the SNP
markers previously found to be associated with ADHD in this
sample.
The field of molecular genetics is dogged by the problem of
subsequent non-replication of new, interesting and apparently
important findings. The current results together with those of
Genro et al. provide strong evidence against an association
between DRD4 and DAT1 risk variants and IQ in ADHD.
Furthermore, in this study there was no evidence that the
broader spectrum of ADHD-related genotypes mediated
the association between ADHD and IQ in this sample. Given
the combined statistical power of the two non-replications and
their breath of ascertainment, the finding byMill et al. may be
a chance false positive. However it is important to consider
differences between the studies and identify alternative
explanations for differences in results between the studies.
The most obvious one of these relates to the nature of the
samples. In sample 1 of Mill et al. (the largest of their two
samples from the British E-risk study) the cases were
epidemiologically ascertained and inclusion in the ADHD
group was primarily based on parent and teacher reports of
symptoms of inattention and overactivity on the basis of an
and/or rule (teacher or/and parent reports met DSM-IV
symptom thresholds). No account was taken of impairment, a
core element of normal diagnosis. This means that a broadly
defined phenotype was employed with only a sub-group who
would receive the clinical diagnosis of ADHD as made in
the current study. One possibility is that in identifying a
genetically at risk intellectually impaired subgroup in their
broadly defined phenotype, they actually isolated those
TABLE II. IQ in the ADHD and Unaffected Siblings as a Function of Level of the Dopamine Genotypic Risk Index
Mill index of dopamine genotypic risk
0 1 2
ADHD combined type 101.8 (16.3), N¼ 190 101.6 (15.0), N¼389 102.9 (16.3), N¼123 F¼ 0.66, P<0.51
Unaffected siblings 103.5 (13.69), N¼188 103.8 (14.8), N¼363 13.4 (14.3), N¼143 F¼ 0.11, P<0.89
Numbers in parentheses are standard deviations.
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childrenwhowouldhavemet the full diagnostic criteriaused in
the current study. This is a reasonable hypothesis since we
already know that ADHD is associated with lower IQ in both
clinical and general populations [Kuntsi et al., 2004].
The studies also differed in relation to exclusion on the basis
of low IQ. In Mill et al. no exclusion was made and IQs ranged
from52 to 147. In the current study childrenwith IQs less than
70 were excluded from the study. This is common practice in
studies of ADHDon the grounds that the conjunction of ADHD
and low IQmay represent a qualitatively distinct presentation
with intellectual impairment playing a more central, and
ADHD a more peripheral role. On the basis of their findings it
seems likely that those children identified as having ADHD
with severe intellectual impairment were over-represented
in the high genotype risk group and perhaps contributed
disproportionately to their findings. This raises the possibility
that the apparent association with IQ in the symptomatic
ADHD group may have had more to do with the genetics of
intellectual impairment of which symptomatic ADHD was
merely a marker.
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